Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amolyt Pharma
A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.
- Large Molecule
- Other Names / Subsidiaries
- Alizé Pharma III
- Alizé Pharma 3